Hyperlipidemia is one of the most common metabolic disorders worldwide, and current first-line drugs such as statins, fibrates, and cholesterol-absorption inhibitors do not work for everyone and can cause side effects. Seeking alternatives, the team turned to herbs long used in traditional medicine. Schisandra chinensis is rich in lignans with documented liver-protective and anti-inflammatory actions. Salvia miltiorrhiza contains water-soluble phenolic acids such as salvianolic acid B alongside tanshinones, compounds shown to improve lipid profiles and protect blood vessels. Hawthorn contributes flavonoids and procyanidins linked to lowered cholesterol and better circulation.

To find the most effective blend, the researchers used a uniform design method, testing 32 different ratios of the three herbs. Each candidate formulation was evaluated in liver cells exposed to excess fatty acids, a laboratory model of lipid overload. The winning ratio—5 parts Schisandra, 3 parts Salvia, and 2 parts hawthorn—was then tested in mice fed a high-fat diet for eight weeks. Animals receiving the formulation showed significantly lower total cholesterol, triglycerides, and LDL cholesterol compared with untreated controls, while liver fat accumulation and liver enzyme levels also declined.

Delving into the mechanism, the team found that the formulation suppressed a key inflammatory pathway in liver tissue. Nuclear factor-kB (NF-kB), a protein complex that switches on genes driving inflammation, remained largely inactive in treated animals. Levels of inflammatory messengers such as tumor necrosis factor-alpha and interleukin-6 dropped in parallel. The researchers also observed reduced activity of acetyl-CoA carboxylase and other enzymes involved in fat synthesis, suggesting the herbs work through both anti-inflammatory and lipid-metabolism routes.

The study provides a scientific foundation for a formulation that has been used empirically for centuries, and the authors suggest it could be developed as a complementary therapy for patients whose hyperlipidemia is not fully controlled by conventional drugs. Further research, including clinical trials in humans, will be needed to confirm safety and efficacy before such a formulation reaches the clinic.

The experimental architecture behind the new findings reflects a deliberate two-tier strategy common in contemporary pharmacology research. By pairing a cell-based system with a whole-animal model, the investigators could first observe lipid-handling effects in a controlled setting and then verify whether those effects translate into systemic changes in living organisms. The HepG2 liver cell line, derived from human hepatocellular carcinoma tissue, is a widely accepted surrogate for studying hepatic lipid metabolism because these cells retain many of the enzymatic pathways that govern cholesterol and triglyceride synthesis, uptake, and export. When flooded with free fatty acids, HepG2 cells accumulate intracellular lipid droplets in a manner that mirrors the fatty change seen in liver tissue from patients and animals with dyslipidemia, making them a useful first screen for candidate lipid-lowering agents.

The choice of C57BL/6 mice for the in vivo arm is equally deliberate. This strain is notably susceptible to diet-induced obesity, hepatic steatosis, and the accompanying disturbances in plasma lipoproteins, which is why it has become the workhorse of nutritionally induced metabolic disease research. Eight weeks of high-fat feeding in these animals reliably produces the constellation of elevated total cholesterol, elevated triglycerides, and depressed high-density lipoprotein cholesterol that defines the human condition the researchers sought to model. The concordance between the cellular and animal results in this study—reduced lipid accumulation in both settings—strengthens the argument that the observed effects are not artifacts of a single experimental system.

Network pharmacology, the computational framework that guided the mechanistic arm of the investigation, represents a conceptual shift in how herbal medicines are studied. Rather than seeking a single active compound acting on a single molecular target, this approach acknowledges that multi-herb formulations exert their effects through constellations of constituents impinging on interconnected biological networks. By mapping the known chemical constituents of the three botanicals against disease-associated genes and proteins, the researchers identified seven molecular targets whose dysregulation appears central to hyperlipidemia: APOB, LDLR, OLR1, PPARG, PRKCA, RXRA, and NCF1. This target panel spans three functional clusters that together paint a coherent picture of how the formulation operates.

The first cluster concerns lipoprotein trafficking. Apolipoprotein B, encoded by APOB, is the structural protein scaffold of very-low-density and low-density lipoprotein particles, and its overproduction drives the delivery of cholesterol-rich particles into the arterial wall. The low-density lipoprotein receptor, encoded by LDLR, performs the opposite function, clearing LDL particles from the circulation by internalizing them into hepatocytes. The finding that the herbal formulation simultaneously suppressed APOB expression and enhanced LDLR expression suggests a coordinated dual action: less lipoprotein is assembled and secreted by the liver, while more is scavenged from the blood. This push-pull dynamic on lipoprotein metabolism is precisely the kind of balanced intervention that single-target drugs often struggle to achieve.

The second cluster links oxidative stress to inflammatory signaling. OLR1, the gene encoding the lectin-like oxidized low-density lipoprotein receptor-1, acts as a sentinel receptor on endothelial cells and macrophages that binds oxidized LDL particles and triggers inflammatory cascades. NCF1, a cytosolic subunit of the NADPH oxidase complex, is a principal generator of reactive oxygen species in phagocytic and vascular cells. PRKCA, the gene for protein kinase C alpha, sits upstream of both oxidative stress amplification and the activation of nuclear factor-kappa B, the transcription factor complex whose phosphorylation and nuclear translocation were directly monitored in this study. The demonstration that the formulation reduced reactive oxygen species production, dampened OLR1 and PRKCA protein levels, and prevented the phosphorylation and nuclear entry of the p65 subunit of NF-kappa B provides a mechanistic thread connecting lipid overload to the inflammatory consequences that make hyperlipidemia dangerous. Chronic activation of this axis is what transforms simple lipid accumulation into arterial wall damage, so interrupting it may confer benefits beyond lipid lowering alone.

The third cluster involves nuclear receptor biology. PPARG, the gene for peroxisome proliferator-activated receptor gamma, is a master transcriptional regulator of adipocyte differentiation, lipid storage, and insulin sensitivity, while RXRA, the retinoid X receptor alpha, serves as the obligatory heterodimerization partner for PPARG and several other nuclear receptors controlling lipid homeostasis. The observed downregulation of both genes in the treated animals suggests the formulation may modulate the transcriptional programs governing fat storage and lipid partitioning, though the precise functional consequences of this suppression in the context of hyperlipidemia remain an area for further dissection.

Methodologically, the study employed a battery of complementary readouts that lend confidence to the conclusions. Oil Red O staining, which selectively labels neutral lipids, provided direct visual and quantitative evidence of reduced hepatic fat deposition, while hematoxylin and eosin staining revealed improvements in liver architecture and diminished signs of cellular injury. Enzyme-linked immunosorbent assays quantified the drop in circulating tumor necrosis factor-alpha and interleukin-6, two cytokines whose elevation is a hallmark of the low-grade systemic inflammation that accompanies dyslipidemia and contributes to atherosclerotic progression. Quantitative reverse transcription polymerase chain reaction and Western blotting confirmed that the changes in target gene expression occurred at both the messenger RNA and protein levels, ruling out purely post-transcriptional artifacts. The dichlorofluorescein-based fluorescence assay for reactive oxygen species and the immunofluorescent tracking of p65 subcellular localization added functional validation to the molecular measurements.

It is worth noting that the formulation was prepared as a water-based decoction, the traditional method of herbal preparation in Chinese medicine, involving sequential reflux extractions of powdered plant material. This approach captures the water-soluble constituents of each herb, including the phenolic acids of Salvia miltiorrhiza and the polar fractions of hawthorn flavonoids, though it may leave behind some lipophilic compounds such as tanshinones that require organic solvents for efficient extraction. The pharmacological profile of the final preparation therefore reflects the collective activity of the water-extractable fraction, and future work may explore whether standardized enrichment of specific constituent classes enhances potency further.

The uniform design methodology used to optimize the three-herb ratio deserves mention as an efficient alternative to full factorial experimentation. By sampling a structured subset of the possible proportion combinations across seven dosage levels for each herb, the researchers could identify an optimal blend with a fraction of the experimental burden that exhaustive testing would require. This statistical approach, originally developed for industrial process optimization, has found increasing application in traditional medicine research where multi-herb formulations present combinatorial challenges that conventional dose-finding designs handle poorly.

Several caveats temper the enthusiasm warranted by these results. The mechanistic targets were identified through computational prediction and validated at the expression level, but direct binding studies demonstrating that specific constituents of the formulation engage these molecular targets remain to be performed. The duration of treatment in the animal model, while sufficient to establish efficacy, does not address the long-term safety profile that any therapeutic candidate must demonstrate. Furthermore, the metabolic context of laboratory mice differs from human hyperlipidemia in important respects, including lipoprotein metabolism and gut microbiome composition, both of which can profoundly influence herbal pharmacology. Clinical translation will require carefully designed human trials with standardized preparations, defined dosing, and rigorous monitoring of both lipid outcomes and adverse events. Nevertheless, the convergence of lipid-lowering, anti-inflammatory, and antioxidant effects observed across multiple experimental readouts positions this three-herb formulation as a scientifically grounded candidate worthy of continued investigation.

Subject of Research: The Schisandra-Salvia-Hawthorn herbal formulation demonstrates therapeutic efficacy in ameliorating hyperlipidemia

Article Title: The Schisandra-Salvia-Hawthorn herbal formulation demonstrates therapeutic efficacy in ameliorating hyperlipidemia

Article References: Xing, N., Qu, H., Jiang, Y., Ge, P., & Ma, W. (2026). The Schisandra-Salvia-Hawthorn herbal formulation demonstrates therapeutic efficacy in ameliorating hyperlipidemia. Frontiers in Pharmacology, 17, Article 1893568. https://doi.org/10.3389/fphar.2026.1893568

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1893568

Keywords: Schisandra chinensis, Salvia miltiorrhiza, hawthorn, hyperlipidemia, herbal formulation, NF-kB, inflammation, lipid metabolism, Schisandra-Salvia-Hawthorn, herbal, formulation, demonstrates

What makes ursolic acid unusual among natural compounds is its multi-targeted mechanism of action. Rather than binding a single receptor, it modulates several major oncogenic pathways simultaneously. The review highlights four in particular: PI3K/AKT/mTOR, MAPK, NF-κB, and JAK/STAT. These pathways are the molecular engines of malignancy. PI3K/AKT/mTOR drives cell survival and metabolism; MAPK governs proliferation and differentiation; NF-κB controls inflammatory transcription that fuels tumor growth; and JAK/STAT relays growth factor and cytokine signals straight to the nucleus. By interfering with all four, ursolic acid inhibits tumor growth, survival, and metastasis in a way that single-target drugs often fail to achieve.

The technical details of how the compound disrupts these circuits are striking. In breast cancer cells, ursolic acid decreases the proliferation of cancer stem-like cells by modulating the ERK and PI3K/AKT signaling pathways. In ovarian cancer, it downregulates PI3K/AKT while mediating ROS and mitochondrial membrane potential-driven apoptosis and cell cycle arrest, and more recent work shows it inhibits glycolysis through the KLF5/PI3K/AKT signaling pathway—cutting off the metabolic reprogramming that ovarian tumors rely on. In osteosarcoma cells, ursolic acid triggers apoptosis via caspase activation and the ERK1/2 MAPK pathway. In leukemia T-cells, it alters cytokine production through the MAPK pathways. The compound also suppresses cyclin B1 to regulate cell cycle and proliferation in colon adenocarcinoma, and in endometrial cancer it acts on MAPK within cyclin D1 signaling and RING-type E3 ligase machinery.

NF-κB suppression is another recurring theme. Ursolic acid induces apoptosis by activating p53 and caspase-3 gene expression while suppressing NF-κB-mediated activation of bcl-2 in melanoma cells. It enhances chemotherapeutic agent-induced apoptosis by inhibiting NF-κB, and in gemcitabine-resistant pancreatic cancer it induces apoptosis via the JNK and PI3K/Akt/NF-κB pathways. In bladder cancer cells, it induces apoptosis through Akt/NF-κB signaling suppression. The compound also upregulates UGT1A1 expression by inhibiting the PKC/NF-κB signaling pathway, and it protects against inflammatory responses in gastric tumor models by blocking NLRP3 inflammasome activation—demonstrating that its anticancer and anti-inflammatory actions are mechanistically intertwined.

The JAK/STAT pathway, particularly STAT3, is a third major target. Ursolic acid inhibits STAT3 activation, leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Inhibition of STAT3 signaling suppresses growth of hepatocellular carcinoma. In non-small cell lung cancer, ursolic acid exerts antitumor effects by blocking STAT3/PD-L1 signaling—a finding with obvious immunotherapy implications, since PD-L1 is the molecular shield tumors use to evade immune attack. In colorectal cancer cells, ursolic acid induces apoptosis partly through upregulation of MicroRNA-4500 and inhibition of JAK2/STAT3 phosphorylation, adding a microRNA layer to its mechanism.

Beyond pathway modulation, the review emphasizes that ursolic acid induces apoptosis through both intrinsic and extrinsic routes. The intrinsic, mitochondrial pathway involves mitochondrial dysfunction, oxidative stress, and caspase-3 activation: in melanoma cells, ursolic acid induces apoptosis through the mitochondrial intrinsic pathway; in breast cancer cells, it acts through both mitochondrial and extrinsic death receptor pathways; in HeLa cells, it induces apoptosis through the mitochondrial pathway and suppression of ERK1/2 MAPK. The extrinsic route engages death receptors on the cell surface, and ursolic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Ursolic acid and its derivatives also induce mitophagy in lung cancer cells, and derivatives evoke apoptosis through endoplasmic reticulum stress. In oral cancer cells, a derivative triggers ROS-dependent p53-mediated mitochondrial apoptosis.

The p53 tumor suppressor is a central node in many of these effects. Ursolic acid induces hepatoma cell apoptosis via a p53-dependent pathway, induces apoptosis of SW480 colon cancer cells via p53 activation, and induces apoptosis in nasopharyngeal carcinoma cells through the p53 signaling pathway. It also ameliorates p53 gene mutation induced by cyclophosphamide, suggesting a protective role against genotoxic damage. Additional mechanisms include suppression of vaccinia-related kinase 1-mediated damage repair in lung cancer cells, promotion of apoptosis through ROCK/PTEN-mediated mitochondrial translocation of cofilin-1 in prostate cancer, and metabolic rewiring with epigenetic reprogramming in prostate cancer cells. Ursolic acid suppresses cholesterol biosynthesis in hepatocellular carcinoma, downregulates ARL4C to inhibit colon cancer metastasis, regulates the TGF-β1/ZEB1/miR-200c signaling pathway to suppress invasion, downregulates Wnt/β-catenin signaling in colorectal cancer, and suppresses TGFβ-mediated epithelial-mesenchymal transition and angiogenesis in glioblastoma.

Drug resistance is where the review turns especially compelling. Ursolic acid sensitizes cisplatin-resistant hepatocellular carcinoma cells to cisplatin by inhibiting the Nrf2/ARE pathway. It restores gemcitabine sensitivity in pancreatic cancer through the RAGE/NF-κB/MDR1 axis, both in cells and in a mouse xenograft model. It enhances the sensitivity of breast cancer cells to epirubicin by modulating the autophagy pathway, and combined use with zoledronic acid augments apoptosis in osteosarcoma through enhanced oxidative stress and autophagy. Synergism with 2-deoxy-D-glucose preferentially induces tumor cell death by dual-targeting apoptosis and glycolysis. The compound disrupts cancer stem cell properties, inhibits ovarian cancer stem-like cells through epithelial-mesenchymal transition, and impairs cellular lipid homeostasis and lysosomal membrane integrity in breast carcinoma cells. It even alleviates cancer cachexia and prevents muscle wasting by activating SIRT1, and inhibits metastasis of doxorubicin-resistant breast cancer.

The obstacle is bioavailability. Ursolic acid is poorly soluble and poorly absorbed, which limits the concentrations reaching tumors. The review catalogs a wave of nanoparticle-based delivery systems designed to overcome this: chitosan-coated PLGA nanoparticles loaded with ursolic acid for breast cancer therapy; folate-chitosan nanoparticles conferring anti-breast cancer activity in vitro and in vivo; PLGA nanoparticles against pancreatic ductal adenocarcinoma; hyaluronic acid-modified polydopamine nanomedicine loaded with ursolic acid and astragaloside IV for combined chemo-immuno-photothermal therapy in non-small cell lung cancer; self-assembled folic acid-targeted pectin-multi-arm PEG nanoparticles for intracellular chemotherapy; carrier-free pure nanodrug self-assembly for cancer immune therapy; poly(N-vinylpyrrolidone)-block-poly(ε-caprolactone) nanoparticles inhibiting hepatocellular carcinoma growth in vitro and in vivo; β-cyclodextrin inclusion complexation enhancing antitumor and antibacterial activities; a bioactive assembly cofactor-assisted ursolic acid helix with enhanced anticancer efficacy via in situ virus-like transition; and multifunctional vesicles combining ursolic acid with kinase inhibitors.

Despite this progress, the review is candid about what remains unknown. The precise molecular mechanisms and optimal therapeutic doses of ursolic acid have not been fully elucidated, and the compound has not yet advanced into clinical cancer therapy. Preclinical evidence spans leukemia, melanoma, breast, lung, ovarian, pancreatic, prostate, colon, thyroid, liver, bladder, gastric, cervical, endometrial, nasopharyngeal, oral, throat, esophageal, and glioblastoma models, with in vivo work in TRAMP mice prolonging survival and orthotopic pancreatic models enhancing gemcitabine’s antitumor potential through suppression of the inflammatory microenvironment. Goyal and Singh position ursolic acid as a candidate complementary or standalone anticancer agent, arguing that with better delivery systems and clearer dose-response data, a molecule found in apple skins could earn a place in the oncology clinic.

Subject of Research: Cancer Research

Article Title: Ursolic acid in cancer therapy: a review of signaling pathways and apoptotic mechanisms

Article References: Goyal, S., & Singh, B. (2026). Ursolic acid in cancer therapy: a review of signaling pathways and apoptotic mechanisms. Molecular Biology Reports, 53(1), Article 1736. https://doi.org/10.1007/s11033-026-12846-z

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12846-z

Keywords: ursolic acid, cancer therapy, apoptosis, PI3K/AKT/mTOR, NF-kB, JAK/STAT, cancer stem cells, nanoparticles, triterpenoid, drug resistance, Ursolic, acid

The review begins with a striking observation about the structure of long COVID itself. Rather than arising from a single defect, the condition appears to involve a self-reinforcing triad of persistent low-grade inflammation, autonomic nervous system imbalance, and metabolic dysfunction. Patients commonly show sustained elevation of inflammatory cytokines such as IL-6, TNF-α, and IL-1β, driven in part by lingering viral antigens, tissue injury, and macrophages locked in a pro-inflammatory state. At the same time, heart rate variability studies reveal a shift toward sympathetic dominance and reduced parasympathetic tone, while immune cells undergo a metabolic switch from efficient oxidative phosphorylation to aerobic glycolysis, depleting ATP, accumulating lactate, and damaging mitochondria through excess reactive oxygen species. Each abnormality amplifies the others, creating a vicious cycle that the authors describe as an inflammation–autonomic–metabolic pathological triad.

At the center of this cycle, the review places the vagus nerve and its cholinergic anti-inflammatory pathway, often abbreviated CAP. The vagus nerve, the tenth cranial nerve, maintains a constant dialogue between the brain and the visceral organs, with roughly 80 percent of its fibers carrying sensory information upward and the remainder delivering regulatory commands downward. When inflammatory signals reach the brainstem’s nucleus tractus solitarius, a reflex arc triggers efferent vagal output that releases acetylcholine onto immune cells in organs such as the spleen and liver. Acetylcholine binds to α7 nicotinic acetylcholine receptors on macrophages, activating a JAK2–STAT3 signaling cascade that suppresses NF-κB, inhibits assembly of the NLRP3 inflammasome, and thereby curtails production of TNF-α, IL-6, and IL-1β. In parallel, the same receptor signaling promotes Nrf2-dependent antioxidant defenses, inducing enzymes such as heme oxygenase-1 and superoxide dismutase.

Crucially, the review argues that the CAP is more than an anti-inflammatory reflex. Cholinergic signaling cross-talks with the AMPK–SIRT1–PGC-1α axis, a trio of metabolic regulators that governs mitochondrial biogenesis, antioxidant capacity, and energy homeostasis. Acetylcholine can enhance AMPK phosphorylation through calcium-dependent mechanisms, while SIRT1 activates PGC-1α by deacetylation, boosting the production of new mitochondria and improving oxidative metabolism. This coupling means that a single neural pathway could, in principle, simultaneously dampen inflammation and rebuild cellular energy supply—precisely the two functions that appear deranged in long COVID. The authors describe the CAP as a regulatory hub where neural, immune, and metabolic control converge, rather than a one-dimensional brake on cytokines.

Building on this anatomy, the review proposes that many long COVID patients may exhibit what it calls CAP hyporesponsiveness—a provisional research descriptor, not a diagnosis—characterized by reduced vagal tone, diminished acetylcholine availability, downregulated α7nAChR expression, and consequently weakened anti-inflammatory feedback. The authors are explicit that heart rate variability reduction alone cannot establish this pattern, since HRV is an indirect and non-specific marker. Instead, they outline candidate mechanistic domains spanning autonomic regulation, cholinergic signaling, inflammatory pathway activation, systemic inflammatory burden, and metabolic-mitochondrial stress, all of which would need to be measured together in prospective studies before the concept could be validated or translated into clinical subtyping.

The strongest evidence that electroacupuncture can engage this pathway comes from animal studies, and the review grades that evidence carefully. In mouse models of sepsis-related lung injury, postoperative ileus, and acute pancreatitis, stimulation at the Zusanli acupoint (ST36) on the lower leg restored α7nAChR expression, inhibited NF-κB signaling, and reduced inflammatory cytokines—and, critically, these protective effects were abolished when researchers cut the vagus nerve or blocked the α7nAChR receptor with antagonists such as methyllycaconitine. Such pathway-disruption experiments provide direct evidence that the vagal–cholinergic axis mediates at least some of electroacupuncture’s anti-inflammatory effects. Other animal work, including studies in diabetic rats, shows that electroacupuncture increases AMPK, PGC-1α, and GLUT4 expression and raises skeletal muscle ATP, supporting the metabolic arm of the proposed framework, though these findings do not by themselves prove CAP involvement.

Human evidence is more indirect but broadly consistent. Clinical studies in healthy volunteers and patients with inflammatory conditions report that electroacupuncture alters heart rate variability in a frequency-dependent manner, increases high-frequency vagal components, reduces sympathetic stress indices, and lowers circulating TNF-α and IL-1β in conditions such as knee osteoarthritis. Functional neuroimaging shows that stimulation at ST36 modulates brain regions involved in somatosensory, limbic, and autonomic processing, and small clinical reports in long COVID patients describe improvements in fatigue, dyspnea, abnormal heart rate, and inflammatory markers alongside enhanced HRV. Because no human study has directly tested CAP dependence through pathway disruption, the authors classify all clinical findings as supportive rather than conclusive, a distinction they maintain throughout the review.

To organize these heterogeneous results, the authors propose an integrated EA–CAP–AMPK–SIRT1–PGC-1α model, in which electroacupuncture stimulation enhances vagal afferent input, activates central autonomic integration in the brainstem, releases acetylcholine onto α7nAChR-expressing immune cells, and thereby suppresses NF-κB and NLRP3 signaling while simultaneously supporting mitochondrial function through the metabolic axis. They supplement this with a Neural Resonance Modulation hypothesis, suggesting that frequency-specific somatosensory input may synchronize rhythmic activity within brainstem–hypothalamic circuits, and with a neuro–immune–metabolic loop framework describing how anti-inflammatory, metabolic, and central integrative processes reinforce one another. The model explicitly distinguishes directly supported links from inferred connections and clinical extrapolations, marking the proposed convergence between CAP signaling and metabolic recovery as biologically plausible but not yet experimentally confirmed.

Looking toward translation, the review outlines phenotype-oriented strategies for future trials, proposing candidate long COVID subgroups—an autonomic-dominant type defined by abnormal HRV and orthostatic intolerance, an inflammatory-immune type marked by elevated CRP and cytokines, a metabolic-mitochondrial type dominated by fatigue and exercise intolerance, and a mixed type—each with tailored acupoints, stimulation frequencies, and outcome measures. Low-frequency stimulation of two to fifteen hertz for twenty to thirty minutes, two to three times weekly, remains the most commonly used protocol. A randomized, sham-controlled trial protocol recently designed to test electroacupuncture for long COVID neuropsychiatric symptoms in 150 patients over 16 weeks may provide the first rigorous test, though results remain pending.

The authors acknowledge substantial obstacles: stimulation parameters and acupoint combinations vary widely across studies, indirect markers such as HRV lack specificity, and mechanistic research has typically examined single pathways rather than the multi-layered coupling their framework proposes. Progress, they argue, will require CAP-centered assessment systems that combine heart rate variability, immunomics, metabolomics, and functional neuroimaging, together with phenotype-stratified randomized trials and, eventually, AI-assisted closed-loop devices that adjust stimulation in real time based on physiological feedback. Whether electroacupuncture ultimately proves effective for long COVID remains an open question, but the review offers something the field has lacked: a structured, evidence-graded map of how a peripheral nerve intervention might plausibly reach the neural, immune, and metabolic networks that this perplexing disease disrupts.

Subject of Research: Electroacupuncture modulation of vagal cholinergic anti-inflammatory and neuro-immune-metabolic pathways in long COVID

Article Title: Integrative perspectives on electroacupuncture modulation of vagal–cholinergic and neuro–immune–metabolic regulation in long COVID

Article References: Wang, L., Hu, X., & Yan, D. (2026). Integrative perspectives on electroacupuncture modulation of vagal–cholinergic and neuro–immune–metabolic regulation in long COVID. Frontiers in Integrative Neuroscience, 20, Article 1775007. https://doi.org/10.3389/fnint.2026.1775007

Image Credits: AI Generated

DOI: 10.3389/fnint.2026.1775007

Keywords: long COVID, electroacupuncture, vagus nerve, cholinergic anti-inflammatory pathway, alpha7 nicotinic acetylcholine receptor, NF-kB, NLRP3 inflammasome, AMPK, SIRT1, PGC-1alpha, mitochondrial dysfunction, autonomic dysfunction

The research team, led by Fan Zhang, Lei Chen, Yong Liu, and Jian Xiao, with collaborators at Wenzhou Medical University, Oujiang Laboratory, and Nankai University, describes a family of materials they call nanozyme-exoskeletonized yeast-derived polysaccharides, abbreviated NZEP. The central idea is a fusion of two biologically familiar components. The first is a polysaccharide scaffold derived from yeast, which provides a large, biocompatible, and biodegradable structure that the digestive tract already knows how to tolerate. The second is a layer of nanozymes, artificial nanoparticles that mimic the catalytic activity of natural enzymes, grafted onto that scaffold in a dense external coating. The result is a microscopic composite that behaves like a single, robust particle with the surface chemistry of yeast and the catalytic power of an enzyme-mimicking nanomaterial.

What makes the construction method particularly striking is its natural model. Rather than relying on conventional polymer chemistry to lock the nanozymes onto the polysaccharide surface, the researchers drew inspiration from insect sclerotization, the process by which insects harden and stabilize their exoskeletons. In sclerotization, phenolic compounds, notably quinone derivatives generated from catechols such as dopamine-like molecules, undergo oxidative coupling and cross-linking reactions that convert a soft cuticle into a tough, chemically resistant armor. By adapting this chemistry, the team was able to coat yeast-derived polysaccharides with a stable, integrated layer of nanozymes, producing what they describe as a series of materials with varying degrees of exoskeletonization. The most heavily armored member of the series, designated NZEP-TA-Ce, emerged as the leading candidate, combining a tannic-acid-based phenolic framework with cerium-based catalytic nanoparticles.

The choice of cerium is central to the material’s therapeutic logic. Cerium oxide nanoparticles are among the most studied antioxidant nanozymes, capable of cycling between cerium(III) and cerium(IV) oxidation states in a way that lets them scavenge reactive oxygen species catalytically, repeatedly, and without being consumed. In the inflamed intestine, oxidative stress is a self-perpetuating driver of tissue damage: reactive oxygen species injure epithelial cells, recruit immune cells, and stimulate further inflammatory signaling, which in turn generates more reactive oxygen species. By embedding catalytic antioxidant activity directly into the particle shell, NZEP-TA-Ce is designed to interrupt this vicious cycle at the source, quenching the oxidative messengers that keep the inflammatory loop running.

The study’s mechanistic findings point to exactly that interruption. According to the authors, NZEP-TA-Ce inhibits inflammatory signaling mediated by two of the most important molecular pathways in intestinal inflammation: the mitogen-activated protein kinase cascade, or MAPK, and the NF-κB pathway. These pathways act as master switches in immune cells and epithelial cells, translating stress and inflammatory stimuli into the production of pro-inflammatory cytokines. When they are chronically activated, as they are in inflammatory bowel disease, the result is a sustained cycle of immune activation, tissue damage, and barrier breakdown. Suppressing both routes simultaneously, the researchers report, allows the material to disrupt the inflammatory feedback loop that sustains the disease, rather than merely damping individual symptoms downstream.

A second advantage of the yeast-derived scaffold lies in its behavior after oral administration, which is the route that matters most for a gut-directed therapy. In mouse models of inflammatory bowel disease, orally delivered NZEP-TA-Ce showed effective retention and accumulation in inflamed colonic regions rather than being washed through indiscriminately. This targeting behavior is thought to arise from interactions between the polysaccharide shell and components of the inflamed tissue environment, an effect long exploited by other yeast-derived microparticles that bind to inflamed intestinal surfaces. Once retained at the site of injury, the material reversed the imbalance of intestinal inflammation and promoted repair of the intestinal barrier, the single-cell-thick lining whose leakage is considered a key event linking gut inflammation to systemic immune activation and, by extension, to disturbances in mood-related brain signaling.

The third and perhaps most novel dimension of the study concerns the gut microbiota. NZEP-TA-Ce treatment reversed dysbiosis, the characteristic disruption in the composition of the intestinal microbial community that accompanies inflammatory bowel disease. The microbiome is not a passive bystander in either the gut disease or its psychiatric comorbidities. Microbial metabolites, including short-chain fatty acids and other small molecules produced by bacteria as they ferment dietary fiber, travel through the bloodstream and act on immune cells, the vagus nerve, and brain circuits involved in anxiety and depression. The researchers report that the treatment optimized the composition of these microbial metabolites, restoring a metabolic profile more consistent with a healthy gut community. In doing so, the therapy addressed the molecular messengers thought to carry inflammatory and mood-related signals between gut and brain.

The combined effect of these three actions, catalytic anti-inflammatory activity, barrier repair, and microbiota modulation, translated into behavioral improvement in the animal models. Mice receiving NZEP-TA-Ce showed alleviation of the anxiety-like and depressive symptoms associated with inflammatory bowel disease, in parallel with the improvement in their intestinal pathology. This is the aspect of the work most likely to capture attention beyond the gastroenterology community, because it demonstrates in a single orally delivered material a therapeutic strategy aimed simultaneously at a physical disease and its psychological comorbidities. Most existing approaches treat the two conditions in parallel with separate drugs, an approach that ignores the mechanistic overlap the gut-brain axis research of recent years has done so much to illuminate.

The study also emphasized safety, a nontrivial consideration for any nanomaterial intended for repeated oral use. Yeast-derived polysaccharides such as beta-glucans have a long history of safe dietary and pharmaceutical use, and the exoskeletonization strategy embeds the catalytic metal particles within a biocompatible matrix, potentially limiting their free interaction with host tissues. The work was supported by the National Natural Science Foundation of China, the National Science and Technology Major Project for Innovative Drug Research and Development, the Natural Science Foundation of Zhejiang Province, and municipal research programs in Wenzhou, and it was conducted with institutional support from Wenzhou Medical University and Oujiang Laboratory. The authors report no competing interests.

As with any mouse study, the distance to human medicine remains substantial. Human inflammatory bowel disease is more heterogeneous than the models used in the laboratory, and behavioral readouts in mice only approximate the clinical experience of anxiety and depression. Dosing, long-term biodistribution of the cerium nanozymes, and manufacturing consistency at scale will all require further work before clinical trials could be contemplated. Even so, the study stands out as a demonstration of a design philosophy likely to shape future research: rather than choosing between anti-inflammatory drugs, barrier protectants, and microbiome therapies, it combines all three functions in one bioinspired composite, using nature’s own engineering solutions, from insect armor to yeast architecture, as the blueprint. For the millions of patients whose bowel disease and mood disorder reinforce one another, that integrated vision of treatment is a direction worth watching closely.

Subject of Research: A nanozyme-exoskeletonized yeast polysaccharide therapy for inflammatory bowel disease with comorbid anxiety and depression

Article Title: Bioinspired nanozyme-exoskeletonized yeast-derived polysaccharides for treating comorbid anxiety and depression in inflammatory bowel disease

Article References: Zhang, F., Chen, L., Wang, S., Chen, X., Du, K., Song, F., Jiang, L., Feng, Y., Du, S., Jiang, T., Liu, Y., & Xiao, J. (2026). Bioinspired nanozyme-exoskeletonized yeast-derived polysaccharides for treating comorbid anxiety and depression in inflammatory bowel disease. Nature Communications. https://doi.org/10.1038/s41467-026-78633-3

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78633-3

Keywords: nanozymes, yeast polysaccharides, inflammatory bowel disease, anxiety, depression, gut-brain axis, gut microbiota, intestinal barrier, NF-kB, MAPK, cerium oxide, biomaterials

The central surprise of the study lies in the asymmetry of this crosstalk. When the team exposed human monocytes and macrophages to TNF and IL-4 together, they expected the classic pattern of mutual cross-inhibition that has dominated the literature on antagonistic cytokine pairs. What they observed instead was cooperation. TNF functioned predominantly as a partner that expanded and intensified the set of genes switched on by IL-4, rather than as a brake. The interleukin’s own signature was not blunted by the presence of the inflammatory signal; it was broadened by it. This finding suggests that the anti-inflammatory cytokine does not merely survive contact with its proinflammatory counterpart but actively exploits TNF signaling to shape the scope of its own transcriptional output.

The selectivity of the reverse direction is equally striking. IL-4 did not shut down TNF signaling wholesale. Instead, it targeted a specific component of the TNF-induced program: the interferon response. Genes driven by interferon regulatory pathways, which form an important antimicrobial and immune-activating arm of TNF signaling, were selectively inhibited by IL-4. The broader inflammatory gene expression elicited by TNF, however, remained largely intact. In other words, IL-4 pruned the interferon branch of the TNF response while leaving the rest of the inflammatory tree standing. This level of precision implies that the two cytokines negotiate at the level of individual gene programs rather than through a simple global on-off switch.

Among the genes that responded synergistically to the combined cytokines were sets with well-recognized roles in regulating inflammation and promoting tissue repair. When TNF and IL-4 were present together, these gene sets were induced to levels far exceeding what either cytokine achieved alone. The synergy was not a minor quantitative effect confined to a handful of transcripts; it encompassed coordinated gene programs that shape how macrophages behave in damaged tissue. Because macrophages are central orchestrators of the transition from inflammation to repair, the identity of the genes governed by this combined signal carries weight for understanding how wounds progress from the inflammatory phase to the rebuilding phase.

To test whether this laboratory-scale crosstalk mattered in a living tissue context, the investigators turned to a skin wound-healing model. Their analysis revealed that the synergistically induced gene sets were highly expressed during precisely the phase of wound repair when TNF and IL-4 are co-expressed in the healing tissue. This temporal overlap is biologically meaningful. It suggests that the cooperative program observed in cultured human monocytes is not an artifact of the dish but reflects a naturally occurring transcriptional state in which the two cytokines act together in time and space. During the window when inflammation and repair must be balanced, the combined TNF and IL-4 signal appears to help define the macrophage phenotype that supports that balance.

Mechanistically, the study traced the crosstalk to epigenetic chromatin-mediated mechanisms rather than to changes in signaling alone. Transcription factors are the proteins that bind DNA and switch genes on, but whether they can reach their targets depends on the state of the chromatin, the packaged form of DNA in the cell. The researchers found that cooperation between NF-κB, the canonical transcription factor activated by TNF, and STAT6, the transcription factor activated downstream of the IL-4 receptor, underpinned the synergistic gene expression. Rather than acting through separate gene sets, these two pathways converged on shared regulatory elements, allowing a proinflammatory signal and an anti-inflammatory signal to jointly open and activate the same loci.

A second epigenetic mechanism involved the erasure of a repressive histone mark. Histone H3 lysine 27 trimethylation, abbreviated H3K27me3, is a chemical modification of chromatin that is generally associated with silenced or po genes held in a inactive state. In the presence of the combined cytokine signal, this negative mark was removed from relevant genomic regions, lifting a layer of repression and permitting transcriptional activation. The removal of H3K27me3 provides a plausible explanation for how the synergy produces gene induction that neither cytokine can accomplish alone: TNF signaling through NF-κB helps remodel the chromatin landscape in a way that makes IL-4-driven, STAT6-dependent transcription possible at genes that would otherwise remain closed.

The third mechanistic pillar was the selective inhibition of IRF1, a transcription factor that mediates interferon responses and contributes to the interferon arm of TNF signaling. By suppressing IRF1, IL-4 was able to disassemble the interferon component of the TNF program without dismantling TNF-driven inflammatory gene expression more broadly. This selective targeting helps explain the otherwise paradoxical combination of results: cooperation at repair-related and inflammation-regulating genes on one hand, and selective antagonism at interferon-responsive genes on the other. The crosstalk is therefore not a single mechanism but a coordinated set of chromatin-level events that produce different outcomes at different classes of target genes.

The authors frame these results as identifying a mechanism for the expansion of the IL-4 response, and the implications extend beyond basic cytokine biology. If TNF signaling is required for the full breadth of the IL-4 program in monocytes and macrophages, then broadly suppressing TNF, as many anti-TNF therapies do in conditions such as rheumatoid arthritis and inflammatory bowel disease, may have consequences that reach into the tissue-repair arm of immunity, not only the inflammatory arm. The study also highlights the complexity of crosstalk between antagonistic cytokines more generally, showing that pairs of signals long assumed to cancel each other out can instead cooperate on select gene responses that are important for immune function and tissue repair. Cross-inhibition, the traditional focus of the field, turns out to be only part of the story.

As with any study, the findings come with scope conditions worth keeping in view. The human cell work was performed in primary monocytes and macrophages, and the in vivo evidence comes from a skin wound-healing model, so extending the conclusions to other tissues, other disease settings, and other cytokine combinations will require further investigation. Nevertheless, the work offers a concrete and testable framework: antagonistic cytokines negotiate through transcription factor cooperation, targeted histone modification, and selective inhibition of intermediary factors such as IRF1. For a field that has long organized itself around the idea that inflammatory and anti-inflammatory signals are opponents, the demonstration that TNF can serve as a costimulator of the IL-4 program, and that the two jointly govern genes central to repair, is a reminder that the immune system’s wiring is built less on simple opposition than on context-dependent partnership.

Subject of Research: Crosstalk between the cytokines TNF and IL-4 in regulating gene expression in human monocytes and macrophages

Article Title: IL-4 exploits TNF signaling to shape its gene expression signature in monocytes and macrophages

Article References: Yuan, R., Yang, C., Mishra, B., Oliver, D., Bell, R. D., & Ivashkiv, L. B. (2026). IL-4 exploits TNF signaling to shape its gene expression signature in monocytes and macrophages. Nature Communications. https://doi.org/10.1038/s41467-026-78528-3

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78528-3

Keywords: IL-4, TNF, monocytes, macrophages, cytokine crosstalk, NF-kB, STAT6, H3K27me3, IRF1, gene expression, wound healing, immunology

JI-017 is not a single molecule but a blend of extracts from three medicinal plants: Angelica gigas, Aconitum carmichaeli Debeaux, and Zingiber officinale Roscoe, combined in a precise 2:1:1 ratio. Each component has a long history in traditional Korean medicine, and earlier work by some of the same researchers had shown that the formulation could suppress STAT3 signaling and trigger endoplasmic reticulum stress-mediated apoptosis in hepatocellular carcinoma models. But inflammation and cancer biology share deep molecular roots, and the team suspected that the same multi-component architecture that made JI-017 interesting in oncology might also make it relevant to sepsis, a disease in which no single drug target has proved sufficient.

To explore that hypothesis systematically, the investigators began in silico. They mined the GeneCards and NCBI Gene databases using the names of the three herbs and twelve of their signature compounds, including decursin, nodakenin, aconitine, hypaconitine, 6-gingerol, and 6-shogaol. After standardizing gene symbols to official HGNC nomenclature and removing duplicates, they assembled a set of 233 genes associated with JI-017. Crossing this list against 3,622 sepsis-related genes curated from GeneCards revealed 91 shared genes, a substantial overlap that suggested the formulation’s molecular targets intersect meaningfully with sepsis biology. Protein-protein interaction analysis using the STRING database showed that the JI-017-associated genes formed a densely connected network of 151 nodes and 1,952 edges, indicating that the formulation’s putative targets do not operate in isolation but cluster within coordinated functional modules.

The prioritization analysis sharpened the picture further. When the researchers ranked all sepsis-related genes by their GeneCards relevance scores and selected the top 10 percent as an exploratory subset, 42 of the 91 shared genes fell within that high-priority group. Mapping these genes onto the Kyoto Encyclopedia of Genes and Genomes highlighted their concentration in the Toll-like receptor signaling pathway, the canonical route by which immune cells detect bacterial lipopolysaccharide, or LPS, and launch the inflammatory cascades that include the MAPK and NF-κB pathways. This computational groundwork pointed the team toward macrophages, the sentinels of innate immunity, as the logical cellular testing ground.

In the laboratory, the researchers turned to RAW 264.7 murine macrophages, a workhorse cell line for inflammation research. Safety came first: a WST-8 viability assay across a double-fold dilution series from 100 to 0.7813 micrograms per milliliter showed that concentrations of 25 micrograms per milliliter and above significantly reduced cell viability, so subsequent anti-inflammatory experiments used lower, non-toxic doses. When macrophages were stimulated with LPS and co-treated with JI-017 at concentrations from 10 down to 1.25 micrograms per milliliter, nitric oxide production, normalized to cell viability, fell in a dose-dependent manner, with the three highest concentrations all reaching statistical significance at p less than 0.0001 compared with LPS alone.

The cytokine data were equally striking. Enzyme-linked immunosorbent assays of culture supernatants revealed that JI-017 at 10 micrograms per milliliter significantly reduced secretion of TNF-α, IL-1β, IL-6, and, notably, the anti-inflammatory cytokine IL-10, alongside the chemokines CXCL-1 and CXCL-2. Quantitative real-time PCR confirmed that the suppression occurred at the transcript level, with mRNA levels of TNF-α, IL-1β, IL-6, inducible nitric oxide synthase, cyclooxygenase-2, IL-10, CXCL-1, and CXCL-2 all significantly decreased in the treated group. Western blotting independently verified reduced protein expression of iNOS and COX-2, the two enzymes most responsible for producing nitric oxide and inflammatory prostaglandins during macrophage activation. The authors interpret the simultaneous reduction of pro- and anti-inflammatory cytokines as evidence of a general dampening of LPS-driven transcriptional activation rather than a specific polarization of the immune response toward any particular state.

One of the study’s most technically interesting findings, however, was what the researchers did not observe. Given that JI-017 so effectively suppressed downstream inflammatory mediators, the team expected to find reduced phosphorylation of the upstream signaling proteins ERK, JNK, NF-κB, and IκB. Instead, under the experimental conditions examined, co-treatment with JI-017 did not reduce LPS-induced phosphorylation of any of these proteins. The authors are careful to note that different LPS concentrations were used across the various assays and that these results do not establish a MAPK- or NF-κB-independent mechanism. But the disconnect between intact upstream signaling and suppressed downstream output is genuinely puzzling, and it raises the possibility that the formulation acts at a level that standard phosphorylation readouts do not capture, perhaps through transcriptional regulation, chromatin modification, or mRNA stability. Identifying that mechanism is now a central question for follow-up work.

The in vivo experiments provided the study’s most clinically resonant results. Male C57BL/6 mice received an intraperitoneal injection of JI-017 at 12.5 milligrams per kilogram one hour before a lethal dose of LPS at 20 milligrams per kilogram, with dexamethasone at 5 milligrams per kilogram serving as a positive control. Over 96 hours of monitoring, Kaplan-Meier survival analysis across all five experimental groups yielded a highly significant overall log-rank statistic of 39.86 with four degrees of freedom and a p value below 0.0001, and the JI-017-treated group was associated with improved survival relative to the LPS-only animals. Twenty-four hours after the LPS challenge, serum levels of IL-1β, IL-6, IFN-γ, CXCL-1, and CXCL-2 were all significantly lower in the JI-017 group, and liver tissue showed reduced mRNA expression of IL-1β, IL-6, CXCL-1, and CXCL-2. Descriptive histopathological examination of hematoxylin and eosin-stained liver sections indicated less prominent tissue damage and inflammation in the JI-017 and dexamethasone groups compared with the LPS-only group, while mice receiving JI-017 alone showed no obvious abnormalities.

The translational logic behind the study is worth emphasizing. Current anti-inflammatory therapies for sepsis, including corticosteroids, work by broadly suppressing immune signaling, which can leave patients vulnerable to secondary infections and impaired pathogen clearance. Excessive inhibition of upstream inflammatory pathways has been repeatedly linked to sepsis-induced immunosuppression. A formulation that reduces inflammatory mediator output without measurably blunting MAPK and NF-κB activation could, in principle, offer a gentler modulation of the inflammatory response, though the authors stress that this possibility remains speculative until the mechanism is defined and immune function during infection is directly tested.

The limitations of the work are candidly acknowledged and considerable. The LPS-induced endotoxemia model captures an acute inflammatory response to bacterial cell wall components but does not reproduce the infectious, polymicrobial complexity of clinical sepsis. The serum ELISA and liver qPCR analyses rested on only three samples per group after exclusions, the histopathological observations were exploratory and unblinded, and batch-specific quality-control documentation for the JI-017 formulation was not available, limiting assessment of its chemical standardization. The in vivo dose was selected from a single preliminary survival experiment without dose-response, pharmacokinetic, or exposure analyses. Even so, the convergence of network pharmacology, cellular evidence, and survival data paints a coherent preliminary picture: a centuries-informed herbal combination, rigorously tested with modern tools, may hold therapeutic value for one of medicine’s deadliest syndromes. The authors call for dose-response, pharmacokinetic, safety, and infection-based sepsis studies as the necessary next steps before JI-017 can be considered a serious candidate for clinical translation.

Subject of Research: Anti-inflammatory effects of the multi-herbal formulation JI-017 in macrophages and an LPS-induced endotoxemia model

Article Title: Anti-inflammatory effects of JI-017 in cellular and an LPS-induced endotoxemia model

Article References: Kim, Y.-H., Lee, S.-E., Choi, G.-E., Kim, D.-E., Cheon, C.-H., & Ko, S.-G. (2026). Anti-inflammatory effects of JI-017 in cellular and an LPS-induced endotoxemia model. Molecular Biology Reports, 53(1), Article 1693. https://doi.org/10.1007/s11033-026-12864-x

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12864-x

Keywords: sepsis, JI-017, herbal formulation, inflammation, macrophages, lipopolysaccharide, endotoxemia, NF-kB, MAPK, cytokines, Toll-like receptor signaling, natural products

Diabetic kidney disease is the leading cause of end-stage kidney disease worldwide, and even with modern therapies, many patients continue to progress toward dialysis. At the heart of the damage sit podocytes, specialized cells whose interlocking foot processes form the final barrier that stops proteins from leaking into the urine. When podocytes are injured and lost, proteinuria and glomerulosclerosis follow, and the process is largely irreversible. Two pathways have long been implicated: the toxic accumulation of the lipid ceramide in glomeruli, and the loss of calcium homeostasis that shatters the podocyte’s delicate cytoskeleton. What was missing was the physical link between the two, the precise molecular event that turns fat overload into a calcium catastrophe.

To find it, the team, led by Aiping Duan and Hao Bao of Jinling Hospital and Nanjing University, performed an integrated analysis of gene and protein expression data from diabetic glomeruli, drawing on public datasets including GSE142025, GSE236426 and GSE96804. Using elastic net regression, bootstrap resampling, cross-validation and permutation testing to separate genuine disease hubs from statistical noise, they ranked candidate genes and focused on Adipocyte Enhancer-Binding Protein 1, or Aebp1. Its expression rose steadily as kidney function declined, and immunofluorescence staining of human biopsy tissue confirmed that the protein accumulated prominently in injured podocytes, a pattern mirrored in a mouse model of diabetes induced by streptozotocin and a high-fat diet.

The researchers then asked whether Aebp1 was merely a bystander or an active culprit. Injecting an Aebp1-overexpressing adenovirus into the renal cortex of healthy mice was enough to trigger proteinuria, glomerulosclerosis and the characteristic flattening of podocyte foot processes seen under the electron microscope. Conversely, mice engineered to lack Aebp1 specifically in podocytes were substantially protected: after induction of diabetes, they showed less protein leakage, less scarring and better-preserved filtration architecture. The same protective effect appeared in a second model, adriamycin-induced nephropathy, suggesting that the pathway is not unique to diabetes but may operate across proteinuric kidney diseases, including focal segmental glomerulosclerosis.

The mechanistic trail began with lipidomics. When the team forced Aebp1 expression in cultured mouse podocytes, digital RNA sequencing showed more than three thousand genes changing, with the altered genes heavily enriched in cytoskeletal pathways. Untargeted lipidomics revealed 213 differentially abundant lipids, and among them ceramides and sphingomyelins topped the list. Treating podocytes with C16-ceramide alone reproduced the cytoskeletal collapse, while genetic knockout of Aebp1 in diabetic mice blunted ceramide accumulation in their podocytes. The lipid was not just a correlate; it was sufficient to cause the damage pattern.

How does Aebp1 raise ceramide in the first place? The answer ran through inflammation. Aebp1 overexpression degraded the inhibitory protein IkB-alpha and drove phosphorylated NF-kB p65 into the nucleus, and luciferase reporter assays confirmed that NF-kB binds directly to the promoter of Neu3, a gene encoding a sialidase enzyme central to the ceramide salvage pathway. Blocking NF-kB with the inhibitor BAY 11-7082 suppressed both the Neu3 surge and the ceramide buildup. The chain of command, from Aebp1 through NF-kB to Neu3 to ceramide, held up in diabetic mouse kidneys as well as in culture dishes.

The study’s boldest claim concerned what ceramide does next. Screening calcium channel genes, the researchers found that Trpc6 and Calhm2 both rose after ceramide treatment, but Calhm2, a channel previously studied in the brain and never implicated in kidney physiology, responded most dramatically. Overexpressing Calhm2 raised intracellular calcium and disrupted the cytoskeleton; silencing it blunted the response. Crucially, ceramide did more than increase the channel’s abundance. Within fifteen minutes, ceramide triggered a dose-dependent calcium surge in podocytes, amplified by Calhm2 overexpression and abolished by Calhm2 knockdown, indicating direct activation of the channel by the lipid.

Structural evidence sealed the argument. Molecular docking simulations using the cryo-EM structure of human Calhm2 predicted a hydrogen bond between ceramide and the glutamine residue at position 232 of the channel. Surface plasmon resonance then measured a binding affinity of 1.225 micromolar, a strength consistent with a genuine regulatory interaction. In effect, the researchers had caught a lipotoxic metabolite in the act of opening a gate: ceramide binds Calhm2, calcium floods in, and the podocyte’s actin scaffolding comes apart. This lipid-gated mechanism differs from the mechanical and receptor-mediated activation described for Trpc6 and Piezo1, broadening the framework of how calcium dysregulation injures the kidney filter.

The translational payoff came from urine. Analyzing samples from 55 patients with biopsy-proven diabetic kidney disease and 20 healthy controls, the team found that urinary Aebp1 mRNA levels clearly separated patients from controls, achieving an area under the receiver operating characteristic curve of 0.924, which held up under cross-validation at 0.850. More importantly, urinary Aebp1 correlated with 24-hour proteinuria and independently predicted the severity of glomerulosclerosis on biopsy: after adjusting for tubular fibrosis, age and gender, each unit increase in log-transformed expression corresponded to roughly a four-unit rise in the proportion of scarred glomeruli, explaining about 21 percent of the remaining variance.

The biomarker also looked forward. Over a follow-up extending to 55 months, patients with high baseline urinary Aebp1 faced a significantly higher cumulative incidence of the study’s renal endpoint, a 30 percent or greater decline in estimated glomerular filtration rate. Restricted mean survival time analysis showed high-expression patients losing about 7.4 months of event-free time over 42 months, and penalized multivariable logistic regression yielded an adjusted odds ratio of 4.31 for kidney function decline after accounting for baseline eGFR. The authors caution that the cohort is modest and that upstream triggers of Aebp1, the roles of other ceramide chain lengths, and definitive in vivo tests of Neu3 and Calhm2 remain open questions. But the core message is striking: a fat molecule, a previously obscure calcium channel, and a measurable urinary signal now form a single, testable pathway, one that repositions lipids as active signaling molecules and offers clinicians a noninvasive window into the health of the kidney’s most vulnerable cells.

Subject of Research: The role of Aebp1, ceramide and the Calhm2 calcium channel in podocyte injury in diabetic kidney disease

Article Title: Aebp1 drives a ceramide-gated Calhm2 calcium influx that injures podocytes in diabetic kidney disease

Article References: Duan, A., Jiang, Y., Wang, X., Chen, Z., Dong, P., Guo, Z., Qin, W., & Bao, H. (2026). Aebp1 drives a ceramide-gated Calhm2 calcium influx that injures podocytes in diabetic kidney disease. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.10.017

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.10.017

Keywords: diabetic kidney disease, podocytes, Aebp1, ceramide, Calhm2, calcium signaling, NF-kB, Neu3, glomerulosclerosis, urinary biomarker, lipotoxicity, focal segmental glomerulosclerosis

The review, which systematically evaluated 21 preclinical studies of curcumin and its engineered formulations in ovarian cancer models, arrives at a nuanced conclusion. Curcumin, the authors report, appears to act on multiple molecular signaling pathways that ovarian cancer cells depend upon for survival, proliferation, and spread. These include the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mechanistic target of rapamycin (mTOR) axis, the nuclear factor kappa B (NF-κB) pathway, the Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) cascade, and the Wnt/β-catenin signaling system. Each of these pathways plays a well-documented role in driving the malignant behavior of ovarian tumors, and the fact that a single dietary compound can modulate all of them simultaneously is precisely what has kept curcumin at the center of so much research attention.

The mechanistic details emerging from the reviewed studies are striking in their breadth. In cell culture and animal models, curcumin treatment was consistently associated with increased apoptosis, the programmed self-destruction of cancer cells, alongside reduced cellular proliferation. The compound also appears to inhibit epithelial-to-mesenchymal transition, or EMT, the developmental program that cancer cells hijack to become mobile, invasive, and resistant to therapy. EMT is considered a central driver of metastasis in ovarian cancer, a disease that spreads by seeding the peritoneal cavity rather than primarily through the bloodstream, so any agent that suppresses this plasticity is of considerable interest. One cited study found that curcumin prevented EMT-mediated ovarian cancer progression through the Nrf2/ETBR/ET-1 axis while simultaneously protecting kidney mitochondria from the damaging effects of cisplatin, suggesting a possible dual benefit of tumor suppression and protection of healthy tissue during chemotherapy.

Perhaps the most clinically relevant finding across the reviewed literature is curcumin’s apparent capacity to re-sensitize resistant tumors to standard chemotherapeutic agents. In several preclinical models, curcumin enhanced the effectiveness of cisplatin and paclitaxel, the two backbone drugs of ovarian cancer treatment. A 2025 study cited in the review demonstrated that pre-treatment with curcumin re-sensitized cisplatin-resistant SKOV3 ovarian cancer cells to the drug, while other work showed that curcumin regulated the miR-9-5p/BRCA1 axis to boost paclitaxel’s anti-cancer efficacy. A separate co-delivery study found that packaging curcumin together with the tumor suppressor protein p53 in a nanoparticle system enhanced the sensitivity of drug-resistant ovarian cancer cells to cisplatin. These findings speak directly to the central clinical problem in ovarian cancer management: platinum resistance, which transforms a treatable disease into a largely incurable one.

The review also highlights an emerging and, the authors caution, still preliminary frontier: curcumin’s interaction with the tumor microenvironment. Evidence from one recent study suggests that curcumin may influence the polarization of tumor-associated macrophages, the immune cells that tumors recruit and reprogram into allies that suppress anti-cancer immunity and promote growth. By shifting these macrophages away from their tumor-promoting state, curcumin could in principle help restore a more hostile environment for cancer cells. However, Esmaeli and Dehghanpour Dehabadi are explicit that this particular mechanism is currently supported by limited evidence, and they resist the temptation to overstate what remains an early observation. This restraint is characteristic of the review’s overall tone, which consistently distinguishes between well-supported findings and promising but underpowered signals.

Beneath all of this promise, however, lies a problem that has plagued curcumin research for decades: bioavailability. Curcumin in its free form is poorly absorbed by the body, rapidly metabolized, and quickly cleared, meaning that the concentrations achievable in human blood after oral consumption fall far below the levels at which its impressive cellular effects are observed in the laboratory. This pharmacokinetic weakness explains why decades of encouraging preclinical data have not translated into an approved curcumin-based cancer therapy, and it is the central obstacle that the review’s second major theme, nanotechnology, is designed to overcome.

The reviewed studies describe a diverse arsenal of curcumin nanoformulations, including polymeric micelles, dendrosomes, liposomes, and core-shell nanoparticles, all engineered to protect the fragile polyphenol from degradation and deliver it more effectively to tumor tissue. The evidence suggests these systems substantially improve curcumin’s bioavailability and therapeutic performance compared with the free compound. One particularly inventive example cited in the review is a curcumin-loaded nanoparticle that undergoes phase transformation when exposed to low-intensity focused ultrasound, creating a tumor-targeted and pH-sensitive theranostic platform that combines treatment and imaging in a single vehicle. Another study documented that nanocurcumin preserved kidney function and hematological parameters in rats with chemically induced ovarian cancer treated with cisplatin, pointing toward a protective, supportive role alongside conventional therapy.

Nanoformulations also appear to amplify curcumin’s chemosensitizing effects. Dendrosomal nanocurcumin combined with oxaliplatin downregulated matrix metalloproteinases, enzymes that facilitate tissue invasion, in ovarian cancer cell lines, while curcumin nanoparticles enhanced cisplatin’s anticancer effect in rat ovarian carcinoma by inhibiting both the PI3K/AKT and JAK/STAT3 pathways. Co-delivery systems that package curcumin alongside conventional drugs, such as docetaxel-loaded nanomicelles, have shown enhanced anti-ovarian cancer activity in preclinical settings. Even synthetic derivatives of curcumin are entering the picture: the derivative ST09 was found to modulate the miR-199a-5p/DDR1 axis and regulate proliferation and migration in ovarian cancer cells, and ruthenium complexes bearing curcuminoid ligands showed antiproliferative activity against the A2780 ovarian tumor cell line while modulating NF-κB signaling.

The authors of the review are careful to frame all of this within its proper limits. Every one of the 21 studies they evaluated was preclinical, conducted in cell lines or animal models, and the field has learned repeatedly that dramatic results in a dish or a mouse do not guarantee success in patients. Early-phase clinical trials of curcumin in other contexts have established that the compound is generally safe and tolerable at high doses, and pharmacokinetic studies of various bioavailable formulations in healthy volunteers have mapped out how different delivery strategies affect curcumin’s absorption. But no clinical trial has yet confirmed that curcumin, in any formulation, improves outcomes for women with ovarian cancer. The review’s conclusion is correspondingly measured: curcumin may hold potential as a supportive treatment in ovarian cancer, but further clinical studies are necessary before any such role can be established.

What the review ultimately offers is a rigorous map of where the science currently stands. The mechanistic case for curcumin in ovarian cancer is coherent and multi-layered, spanning survival signaling, inflammatory pathways, metastatic plasticity, the immune microenvironment, and chemoresistance. The nanotechnology angle provides a plausible route around the compound’s longstanding bioavailability problem, and the chemosensitization data suggest that curcumin’s most realistic near-term value may lie not as a standalone therapy but as an adjunct that makes existing drugs work better. For the thousands of women diagnosed each year with a disease that too often resists conventional treatment, the hope is that this accumulating preclinical evidence will soon be tested where it matters most, in well-designed clinical trials.

Subject of Research: Mechanistic and translational potential of curcumin and its nanoformulations in preclinical ovarian cancer models

Article Title: Curcumin in ovarian cancer: mechanistic insights and translational potential

Article References: Esmaeli, M., & Dehghanpour Dehabadi, M. (2026). Curcumin in ovarian cancer: mechanistic insights and translational potential. Medical Oncology, 43(11), Article 333. https://doi.org/10.1007/s12032-026-03454-9

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03454-9

Keywords: curcumin, ovarian cancer, PI3K/Akt/mTOR, NF-kB, JAK/STAT3, Wnt/beta-catenin, nanoparticles, chemotherapy resistance, apoptosis, epithelial-to-mesenchymal transition, tumor microenvironment, drug delivery

The clamworm, distributed across the intertidal zones of Russia, Japan, and China’s Yellow and Bohai Seas, has long been valued as a source of essential fatty acids, trace elements, and an amino acid profile remarkably similar to that of humans. Its enzymatic hydrolysates have previously demonstrated antioxidant, antitumor, and antithrombotic activities. Yet the organism’s poor sensory characteristics, an unpalatable odor and flavor, have limited its use in functional foods. The Maillard reaction, the non-enzymatic browning process that gives roasted coffee and grilled meats their aroma, offered a solution: reacting the protein hydrolysate with reducing sugars both improves flavor and generates new bioactive compounds. Until now, however, studies of clamworm Maillard products had focused almost exclusively on taste, never on liver health.

To prepare the test material, the team first optimized an ultrasound-assisted enzymatic hydrolysis process using a machine-learning-assisted response surface model, treating homogenized clamworm tissue with a neutral protease and flavor protease blend at 50 degrees Celsius for three hours. The resulting hydrolysate was then mixed with L-cysteine and an equal blend of ribose and glucose, and heated at 121 degrees Celsius for 64 minutes to drive the Maillard reaction. Quality criteria based on absorbance at 294 and 420 nanometers confirmed that the reaction had produced the desired browned products, rich in small peptides and modified amino acids.

The animal experiment followed a rigorous design. Six-week-old male ICR mice were divided into three groups of six: a liquid-diet control, an alcohol model group fed the Lieber-DeCarli alcoholic liquid diet for six weeks, and an intervention group that received the same alcohol diet plus a daily gavage of the clamworm Maillard products at 400 milligrams per milliliter. By the end of the study, the alcohol-fed mice had lost significant body weight while their livers swelled, with the liver index climbing from roughly 3.8 percent to 5.4 percent of body weight. Mice receiving the marine extract maintained body weight, liver weight, and liver index statistically indistinguishable from healthy controls, and their livers looked visibly normal, dark red rather than enlarged and discolored.

Under the microscope, the differences were just as striking. Hematoxylin and eosin staining revealed that alcohol feeding had shattered the liver’s orderly architecture, producing extensive inflammatory infiltration, focal hemorrhage, and a marked loss of binucleate hepatocytes. In the treated mice, inflammatory cell invasion was reduced and healthy binucleate hepatocytes returned in greater numbers. Blood chemistry told the same story: serum alanine aminotransferase and aspartate aminotransferase, the classic enzymatic signatures of hepatocyte damage, spiked in the alcohol group and fell significantly in the group given the Maillard products.

Digging into mechanism, the researchers measured three interconnected pathological processes central to alcoholic liver disease. On oxidative stress, alcohol feeding depressed hepatic levels of NRF2, the master transcription factor coordinating antioxidant defense, and simultaneously lowered the activities of the antioxidant enzymes superoxide dismutase and glutathione peroxidase while raising malondialdehyde, a marker of lipid peroxidation. Treatment with the clamworm products reversed every one of these indicators, restoring NRF2 protein, reviving both antioxidant enzymes, and cutting malondialdehyde back down. Because NRF2 controls the genes encoding SOD and GPx, the coordinated recovery suggests the compound helps preserve the cell’s native antioxidant machinery rather than simply scavenging radicals from outside.

Inflammation told a parallel story. Alcohol feeding elevated hepatic NF-κB p65, the core functional subunit of the central inflammatory transcription factor, along with its downstream cytokines tumor necrosis factor-alpha, interleukin-6, interleukin-1 beta, and interleukin-18. The Maillard product intervention significantly suppressed all five. Metabolomics added a fascinating layer: chronic alcohol depleted a whole family of endogenous lipid mediators called N-acyl amino acids, including palmitoyl, stearoyl, oleoyl, linoleoyl, arachidonoyl, and docosahexaenoyl species, which are known to regulate inflammatory signaling. The treated mice restored these mediators, alongside indole metabolites such as indole-3-carboxaldehyde and indoleacrylic acid, which have documented anti-inflammatory and liver-protective effects.

Lipid metabolism formed the third pillar of the protective effect. Alcohol-fed mice showed elevated serum total cholesterol and triglycerides, accumulation of glycerophospholipids such as lysophosphatidylcholines, and a rise in acylcarnitines like propionylcarnitine and acetylcarnitine, hallmarks of incomplete fatty acid oxidation and mitochondrial dysfunction. Crucially, alcohol also depressed hepatic CPT1A, the rate-limiting enzyme that shuttles fatty acids into mitochondria for burning. The clamworm treatment reversed all of these changes, restoring CPT1A protein levels and normalizing the lipid profile, which points to improved mitochondrial beta-oxidation as a key mechanism.

The untargeted metabolomics, performed by ultra-high-performance liquid chromatography coupled to an Orbitrap mass spectrometer, identified 91 differential metabolites between alcohol and control groups and 89 between treatment and alcohol groups, with 45 metabolites shared between the comparisons and reversed by the intervention. Tryptophan-derived metabolites, including L-kynurenine and glutathione itself, were depleted by alcohol and restored by treatment, tying the redox and immune findings together. Complementary experiments in AML12 mouse hepatocytes confirmed that the products directly reduced ethanol-induced reactive oxygen species and blunted ALT and AST leakage in cells, indicating cytoprotection independent of whole-body factors. Compositional profiling identified 27 significantly changed small molecules, dominated by N-acetyl-cysteine, which increased nearly 1,900-fold, plus arginine, cystine, and small peptides of two to six residues, several of which have known hepatoprotective credentials.

The authors are careful about limits. Metabolite annotations remain putative, the mechanisms are correlational rather than causally proven, the metabolomics cohort was small, and the study lacked in vivo control groups receiving the un-Maillard hydrolysate or plain amino acid and sugar mixtures, though the Maillard products outperformed the plain hydrolysate in cell experiments. Bioavailability, dosing, and toxicity in humans remain unknown. Still, the work delivers a compelling, multi-omics case that a humble marine worm, transformed by one of food chemistry’s oldest reactions, can simultaneously blunt oxidative stress, inflammation, and lipid dysregulation in the alcoholic liver. It is a striking reminder that functional food leads can come from the least glamorous corners of the ocean, and that the next generation of liver-protective nutraceuticals may begin in the intertidal mud.

Subject of Research: Hepatoprotective effects of Maillard reaction products from the marine annelid Perinereis aibuhitensis in a mouse model of alcoholic liver disease

Article Title: Hepatoprotective Effects of Maillard Reaction Products From Perinereis aibuhitensis: Identification and Metabolomic Insights in a Mouse Model of Alcoholic Liver Disease

Article References: Qiao, T., Lu, Y., Teng, T., Deng, Z., Liu, F., & Liu, C.-E. (2026). Hepatoprotective Effects of Maillard Reaction Products From Perinereis aibuhitensis : Identification and Metabolomic Insights in a Mouse Model of Alcoholic Liver Disease. Food Science & Nutrition, 14(10), Article e72417. https://doi.org/10.1002/fsn3.72417

Image Credits: AI Generated

DOI: 10.1002/fsn3.72417

Keywords: alcoholic liver disease, Perinereis aibuhitensis, Maillard reaction products, metabolomics, NRF2, NF-kB, CPT1A, oxidative stress, hepatoprotection, marine peptides, functional food, mouse model

The study, published in PLOS Pathogens by Yu Zhang, Peng Wang and colleagues at the People’s Hospital of Xinjiang Uygur Autonomous Region, focused on the viral gene K15, which sits at the right end of the KSHV genome and encodes a multi-pass transmembrane signaling protein. K15 exists in two highly divergent alleles, known as the prototype (P) and minority (M) forms. In their cytoplasmic signaling domains, the two variants share less than 33 percent amino acid homology, a degree of divergence that suggests they may engage different molecular partners inside infected cells and, potentially, shape disease in different ways.

Xinjiang, a historical crossroads on the Silk Road, offered an unusually informative setting. The region has a high prevalence of Kaposi sarcoma and co-circulating viral genotypes rarely seen together in Western cohorts. Of the 147 patients who passed quality control and genotyping, 107, or 72.8 percent, carried the K15M variant, while 40 carried K15P. That distribution echoes patterns reported in classic Kaposi sarcoma cohorts from Japan and Taiwan and hints that host genetic and evolutionary pressures in Central Asian populations may have favored the M form.

The clinical picture that emerged was striking and, at first glance, paradoxical. Patients carrying the M genotype were significantly less likely to be coinfected with HIV, at 10.3 percent versus 27.5 percent among P carriers, yet they showed higher levels of systemic inflammation, measured by the Systemic Immune-Inflammation Index (SII), the neutrophil-to-lymphocyte ratio, and neutrophil counts. They also suffered lower limb edema far more often, at 37.4 percent versus 20.0 percent, and were less likely to have mucosal involvement. After adjusting for tumor stage, demographics and CD4 T-cell counts, K15M carriage remained an independent predictor of edema, with 2.6-fold increased odds, and of a high inflammatory burden, with an adjusted odds ratio of 5.43 for elevated SII.

To probe whether inflammation actually lies on the causal path between viral genotype and edema, the team used causal mediation analysis, a statistical framework that decomposes an association into direct and indirect components. The Systemic Immune-Inflammation Index significantly mediated 29.0 percent of the genotype-associated effect on edema, with a P value of 0.009. A reverse mediation model, testing whether edema led to inflammation rather than the other way around, failed to reach significance, supporting inflammation’s position upstream in the pathway. Dose-response analysis sharpened the picture further: among K15M carriers, edema risk rose linearly with increasing SII, with an odds ratio of 1.58 per 500-unit increase, whereas no such gradient existed in K15P carriers. The inflammation-edema link, in other words, appears intrinsically tied to the viral genotype.

The mechanistic plausibility rests on the structure of the K15 protein. Its signaling capacity resides in a C-terminal cytoplasmic tail containing SH2- and SH3-binding motifs that recruit Src-family kinases and TRAF adaptor proteins to activate the pro-inflammatory NF-kB and MAPK pathways. The P form has been well characterized as mobilizing these cascades through specific tyrosine-based motifs. The M form, by contrast, shows reduced dependence on the canonical YEEV motif for NFAT activation, and the authors hypothesize that its structurally distinct tail may confer enhanced affinity for inflammatory adaptors or lack the negative regulatory phosphorylation sites present in the P type. Such differences could produce constitutive, unchecked signaling that sustains high-grade systemic inflammation, which in turn promotes vascular permeability and the tissue swelling that clinicians observe as edema.

The genotype also carried prognostic weight. Kaplan-Meier analysis showed significantly inferior progression-free survival among K15M carriers, with a log-rank P value of 0.017, and multivariate Cox modeling yielded an adjusted hazard ratio of 1.87, a borderline but robust estimate confirmed across multiple censoring scenarios in sensitivity analyses. Notably, the deleterious effect was most pronounced in patients with localized disease, where the hazard ratio reached 4.32, suggesting that viral biology can flag danger even when the tumor appears anatomically confined. A dedicated sensitivity analysis restricted to classic Kaposi sarcoma patients preserved the inflammatory signature of K15M, arguing against clinical subtype as a confounder.

To convert these biological insights into a usable clinical instrument, the researchers built a six-factor prognostic nomogram using LASSO Cox regression with cross-validation, maintaining an events-per-variable ratio of 11.2. The model anchors on the K15 genotype and visceral involvement, supplemented by CD4 count, procalcitonin, the lymphocyte-to-monocyte ratio and the neutrophil-to-lymphocyte ratio, the latter two selected over SII to avoid collinearity. The tool achieved a concordance index of 0.761, corrected to 0.743 after bootstrapping with 5,000 resamples, and time-dependent ROC analysis showed areas under the curve above 0.80 at one, two and three years.

The head-to-head comparison with conventional staging was decisive. The nomogram achieved an area under the curve of 0.830, significantly outperforming anatomical stage alone at 0.563 and visceral involvement alone at 0.530, with P values of 0.003 and below 0.001 respectively. Reclassification metrics confirmed substantial gains in predictive accuracy, and decision curve analysis demonstrated net clinical benefit across a wide range of threshold probabilities. When patients were stratified by nomogram score, the high-risk group showed a median progression-free survival of 11.0 months versus 40.0 months in the low-risk group, a separation with a P value below 0.0001 that held regardless of HIV status or tumor burden.

The authors are careful to frame their conclusions within the limits of a single-center, retrospective design. Edema was assessed qualitatively rather than with quantitative metrics, a small fraction of viral genotypes remained unclassified, possibly reflecting recombination or untyped variants, and the mediation results are presented as biologically plausible associations rather than definitive causal proof, since no wet-lab cytokine assays were performed on the archival samples. Even so, the implications are considerable. If the K15M genotype sustains an NF-kB-driven inflammatory program independent of immunodeficiency, then carriers may represent a subgroup amenable to anti-inflammatory or immunomodulatory strategies layered onto conventional therapy, with genotyping serving as a companion diagnostic. More broadly, the study argues that Kaposi sarcoma risk assessment should move from anatomical observation toward biology-driven precision oncology, incorporating the genetics of the virus itself into the clinical calculus, particularly in regions where the M genotype predominates.

Subject of Research: Association of KSHV K15 genetic variants with Kaposi sarcoma aggressiveness and inflammation

Article Title: KSHV K15 genetic heterogeneity is associated with Kaposi sarcoma aggressiveness through modulation of the host inflammatory microenvironment

Article References: Zhang, Y., Wang, P., Zhang, J., Wang, Y., Li, T., Ding, Y., & Kang, X. (2026). KSHV K15 genetic heterogeneity is associated with Kaposi sarcoma aggressiveness through modulation of the host inflammatory microenvironment. PLOS Pathogens, 22(10), e1014615. https://doi.org/10.1371/journal.ppat.1014615

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014615

Keywords: KSHV, Kaposi sarcoma, K15 genotype, inflammation, herpesvirus, edema, prognostic nomogram, precision oncology, mediation analysis, NF-kB, HIV, viral genotyping